Skip to main content
SpringerLink
Log in

Mitochondrial Cardiomyopathies

  • Chapter
  • First Online:
Clinical Cardiogenetics

Abstract

Primary mitochondrial diseases (PMD) are caused by mitochondrial dysfunction due to mutations in nuclear or mitochondrial DNA. Cardiac involvement is present in the majority of patients with cardiomyopathy, arrhythmias, and conduction defects being the most prevalent. Hypertrophic cardiomyopathy is the most frequently encountered cardiomyopathy in PMD but also dilated cardiomyopathy and left ventricular non-compaction can occur. Cardiac symptoms may be the presenting sign of PMD or can be found when screening patients with suspected PMD. Early-onset PMD (0–3 years) is generally more severe with multi-organ involvement than late-onset PMD (adolescence/early adulthood).

Where PMD like Barth syndrome, Sengers syndrome, and MELAS used to be clinical diagnoses, DNA analysis plays an increasingly important role early in the diagnostic process and should be performed as soon as PMD or a mitochondrial cardiomyopathy is suspected. Since mitochondria, and thus mutant mitochondrial DNA, are randomly distributed during the cell cycle, disease phenotype may vary greatly.

Treatment for mitochondrial cardiomyopathies is mainly supportive and comprises a combination of diuretics, beta-blockers, and angiotensin-converting enzyme inhibitors in case of reduced left ventricular systolic function and cardiac device therapy. Furthermore, an increasing number of supplements are being used to improve mitochondrial function and to ameliorate the effects of mitochondrial dysfunction. Despite supportive therapy mortality in mitochondrial cardiomyopathy remains high (up to 84%) and is inversely related to age at presentation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Limongelli G, Tome-Esteban M, Dejthevaporn C, Rahman S, Hanna MG, Elliott PM. Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease. Eur J Heart Fail. 2010;12:114–21.

    Article  CAS  Google Scholar 

  2. Gorman GS, Chinnery PF, DiMauro S, Hirano M, Koga Y, McFarland R, Suomalainen A, Thorburn DR, Zeviani M, Turnbull DM. Mitochondrial diseases. Nat Rev Dis Prim. 2016;2:1–23.

    Google Scholar 

  3. Davison JE, Rahman S. Recognition, investigation and management of mitochondrial disease. Arch Dis Child. 2017;102(11):1082–90.

    Article  Google Scholar 

  4. Muraresku CC, McCormick EM, Falk MJ. Mitochondrial disease: advances in clinical diagnosis, management, therapeutic development, and preventative strategies. Curr Genet Med Rep. 2018;6:62–72.

    Article  Google Scholar 

  5. Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018;391:2560–74.

    Article  CAS  Google Scholar 

  6. El-Hattab AW, Scaglia F. Mitochondrial Cardiomyopathies. Front Cardiovasc Med. 2016;3:1–9.

    Article  Google Scholar 

  7. Limongelli G, Masarone D, Pacileo G. Education in heart mitochondrial disease and the heart. Heat. 2017; 103(5):390–8.

    Google Scholar 

  8. Enns GM. Pediatric mitochondrial diseases and the heart. Curr Opin Pediatr. 2017;29(5):541–51.

    Google Scholar 

  9. Keogh MJ, Steele HE, Chinnery PF. Mitochondrial cardiovascular diseases. In: Kumar D, Elliott P, editors. Cardiovascular genetics and genomics. Cham: Springer; 2018. p. 239–58.

    Google Scholar 

  10. McCormick EM, Muraresku CC, Falk MJ. Mitochondrial genomics: a complex field now coming of age. Curr Genet Med Rep. 2018;6:52–61.

    Article  Google Scholar 

  11. Scaglia F. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics. 2004;114:925–31.

    Article  Google Scholar 

  12. Wahbi K, Bougouin W, Béhin A, et al. Long-term cardiac prognosis and risk stratification in 260 adults presenting with mitochondrial diseases. Eur Heart J. 2015;36:2886–93.

    Article  Google Scholar 

  13. Hsu YHR, Yogasundaram H, Parajuli N, Valtuille L, Sergi C, Oudit GY. MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis. Heart Fail Rev. 2016;21:103–16.

    Article  CAS  Google Scholar 

  14. Khambatta S, Nguyen DL, Beckman TJ, Wittich CM. Kearns-Sayre syndrome: a case series of 35 adults and children. Int J Gen Med. 2014;7:325–32.

    PubMed  PubMed Central  Google Scholar 

  15. Govindaraj P, Khan NA, Rani B, et al. Mitochondrial DNA variations associated with hypertrophic cardiomyopathy. Mitochondrion. 2014;16:65–72.

    Article  CAS  Google Scholar 

  16. Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16:280.

    Google Scholar 

  17. Florian A, Ludwig A, Stubbe-Dräger B, Boentert M, Young P, Waltenberger J, Rösch S, Sechtem U, Yilmaz A. Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy. J Cardiovasc Magn Reson. 2015;17:1–11.

    Article  Google Scholar 

  18. Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015;17:689–701.

    Article  CAS  Google Scholar 

  19. El-Hattab AW, Zarante AM, Almannai M, Scaglia F. Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab. 2017;122:1–9.

    Article  CAS  Google Scholar 

  20. Distelmaier F, Haack TB, Wortmann SB, Mayr JA, Prokisch H. Treatable mitochondrial diseases: cofactor metabolism and beyond. Brain. 2017;140:e11.

    Article  Google Scholar 

  21. Finsterer J, Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol. 2010;33:138–51.

    Article  CAS  Google Scholar 

  22. Samuels C, Koenig MK, Hernandez M. Mitochondrial disorder aggravated by metoprolol. Case Rep Pediatr. 2016;2016:1–3.

    Article  Google Scholar 

  23. Zamorano JL, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.

    Article  Google Scholar 

  24. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18:891–975.

    Article  Google Scholar 

  25. Dreisbach AW, Greif RL, Lorenzo BJ, Reidenberg MM. Lipophilic beta-blockers inhibit rat skeletal muscle mitochondrial respiration. Pharmacology. 1993;47:295–9.

    Article  CAS  Google Scholar 

  26. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association. Eur Heart J. 2013;34:2281–329.

    Article  Google Scholar 

  27. Holmgren D, Wåhlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardiomyopathy in children with mitochondrial disease: clinical course and cardiological findings. Eur Heart J. 2003;24:280–8.

    Article  CAS  Google Scholar 

  28. Debray F-G, Lambert M, Chevalier I, Robitaille Y, Decarie J-C, Shoubridge EA, Robinson BH, Mitchell GA. Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. Pediatrics. 2007;119:722–33.

    Article  Google Scholar 

  29. Norrish G, Cantarutti N, Pissaridou E, Ridout DA, Limongelli G, Elliott PM, Kaski JP. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24:1220–30.

    Article  Google Scholar 

  30. Say RE, Whittaker RG, Turnbull HE, McFarland R, Taylor RW, Turnbull DM. Mitochondrial disease in pregnancy: a systematic review. Obstet Med. 2011;4:90–4.

    Article  CAS  Google Scholar 

  31. Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2017; https://doi.org/10.1038/gim.2017.107.

  32. Smeets HJM, Sallevelt SCEH, Dreesen JCFM, de Die-Smulders CEM, de Coo IFM. Preventing the transmission of mitochondrial DNA disorders using prenatal or preimplantation genetic diagnosis. Ann N Y Acad Sci. 2015;1350:29–36.

    Article  CAS  Google Scholar 

  33. Carroll CJ, Isohanni P, Pöyhönen R, et al. Whole-exome sequencing identifies a mutation in the mitochondrial ribosome protein MRPL44 to underlie mitochondrial infantile cardiomyopathy. J Med Genet. 2013;50:151–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division Pediatrics, Wilhelmina Children’s Hospital,University Medical Center Utrecht, Utrecht, The Netherlands

    Andreas C. Blank, Johannes M. P. J. Breur, Sabine A. Fuchs & Klaas Koop

  2. Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands

    Annette F. Baas

Authors
  1. Andreas C. Blank
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes M. P. J. Breur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sabine A. Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Klaas Koop
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Annette F. Baas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas C. Blank .

Editor information

Editors and Affiliations

  1. Consultant Cardiologist at the OLVG Hospital, Amsterdam, The Netherlands

    Hubert F. Baars

  2. Utrecht University, Utrecht, The Netherlands

    Pieter A. F. M. Doevendans

  3. Amsterdam University Medical Center, Amsterdam, The Netherlands

    Arjan C. Houweling

  4. University Medical Center Utrecht, Utrecht, The Netherlands

    J. Peter van Tintelen

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Blank, A.C., Breur, J.M.P.J., Fuchs, S.A., Koop, K., Baas, A.F. (2020). Mitochondrial Cardiomyopathies. In: Baars, H.F., Doevendans, P.A.F.M., Houweling, A.C., van Tintelen, J.P. (eds) Clinical Cardiogenetics. Springer, Cham. https://doi.org/10.1007/978-3-030-45457-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-45457-9_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-45456-2

  • Online ISBN: 978-3-030-45457-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation